Please sign in to follow a disease.
InnoCare Pharma Inc.
Clinical trials sponsored by InnoCare Pharma Inc., explained in plain language.
A biopharmaceutical company developing treatments for cancer and autoimmune diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New drug doses tested for rare blood cancer
Disease control CompletedThis phase 2 trial tested two different daily doses of the drug orelabrutinib in 40 people with mantle cell lymphoma, a rare blood cancer. The goal was to see which dose works better at shrinking tumors and controlling the disease. Participants included both newly diagnosed and r…
Phase 2 • Sponsor: InnoCare Pharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug ICP-332 tested for safety in small early study
Knowledge-focused CompletedThis early-phase trial tested the safety and tolerability of a new drug called ICP-332 in 24 healthy adults. Participants received either the drug or a placebo in multiple doses. The study is now complete and focused on monitoring side effects and changes in vital signs, ECG, and…
Phase 1 • Sponsor: InnoCare Pharma Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC